Population pharmacokinetic/pharmacodynamic modelling of the effects of axomadol and its Oâ€demethyl metabolite on pupil diameter and nociception in healthy subjects The aim of the present study was to characterize the pharmacokinetic/pharmacodynamic (PK/PD) properties of the active components of axomadol and to quantify their contribution to observed the pupillometric and analgesic (measured through the cold pressor test) effects linking the PD engagement biomarker with clinical response. Healthy subjects (n = 74) received either placebo or axomadol orally at doses ranging from 66 mg to 225 mg following multiple dosing regimens in two separate clinical trials. Plasma concentrations of the two enantiomers of axomadol and their metabolites, and PD responses were measured at specific times
or auralgan or axomadol or befiradol or bicifadine or brivaracetam or brivoligide or bromadoline or "Calcitonin Gene-Related Peptide Receptor Antagonist*" or cannabidivarin or capsaicin or Carbachol or Carbamazepine or cebranopadol or cibinetide or cizolirtine or Clonidine or crobenetine or Cyclazocine or dapansutrile or dasolampanel or davasaicin or deacetyllappaconitine or "Dentin Desensitizing
Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain - Full Text View - ClinicalTrials.gov Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort. Hide glossary GlossaryStudy record managers: refer to the Data Element Definitions if submitting studies (100).Please remove one or more studies before adding more. Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain (CLBP) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details